Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Deals

Jan. 7 Quick Takes: AZ adds another amyloidosis mAb via Neurimmune deal

Plus: a16z’s $9B in new funds earmarks cash for bio, and updates from Virtue, AN2, Ultragenx-Regeneron and more

January 8, 2022 3:17 AM UTC

For $30 million up front, AstraZeneca plc (LSE:AZN; NASDAQ:AZN) will receive exclusive, worldwide rights to NI006 from Neurimmune AG, a mAb in Phase Ib testing to treat cardiomyopathy associated with TTR-mediated amyloidosis (ATTR-CM). The Zurich-based biotech is eligible for $730 million in milestones, plus royalties. Last year, AstraZeneca acquired partner Caelum Biosciences Inc. to gain a mAb to treat light-chain (AL) amyloidosis.

Andreessen Horowitz has raised a $1.5 billion “bio” fund as part of an overall $9 billion raise that also includes $5 billion growth and $2.5 billion venture funds. The firm invests in life sciences companies at the confluence of biology and tech...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article